Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) ( pharmaceutical subsidiary of Eisai Co....)

Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.6 billion in fiscal year 2006 (year ended March 31, 2007). Eisai Inc. employs approximately 1,500 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the- art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. For more information about Eisai, please visit www.eisai.com.

CONTACT: Judee Shuler of Eisai Inc., +1-201-746-2241, During ASCO, +1-908-337-2540

Web site: http://www.eisai.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Page: 1 2 3 4 5 6
Related medicine technology :

1. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
2. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
3. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
4. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
5. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
6. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
7. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
8. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
11. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen

Post Your Comments:

(Date:12/1/2009)...swire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex...loper of vaccines and therapeutics for the prevent...d today that it has retained the services of an in...o run CEL-SCI,s upcoming Phase III clinical trial ...Company,s lead product candidate, Multikine®....

(Date:12/1/2009)...PRNewswire/ -- Sleep Solutions®, Inc. (SSI), ...esting and evaluation of sleep-disordered breathin....D., as its chief executive officer. Hassett was ...ng its growth from a $250 million healthcare holdi...total population health, and its subsequent sale f...

(Date:12/1/2009)... 1 Siemens Hearing Instruments, I...al manufacturer of hearing instruments, announced ...nal,s Sound Beginnings program. The alliance will ... of the renewed partnership, Siemens is expanding ...ng instruments to both children and young adults, ...

Breaking Medicine Technology:CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2 CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3 Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2 Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3 Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2 Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3 Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 1 Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 2 Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 3 Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 4 Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 5 Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 1 Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 2 Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 3 Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 4 Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 1 Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 2 Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 3

[0] CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine [0] Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO [0] Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need

...June 21, 2007 /PRNewswire-FirstCall/ - Biotech,Hol... has given,Biotech,s "Sucanon" diabetes drug its s...in the May-June 2007 issue of Diabetes,Hoy, the Di...e for,doctors and other health professionals. , Th...to Cepeda,Gonzalez, Medical Director of the Specia...

... to Indicate that Early Use of Estrogen May be,Car...-USNewswire/ -- A new analysis,of Women,s Health I...l of Medicine, shows significant reduction in calc... therapy (HT) compared,with women taking a placebo...estrogen therapy and coronary artery calcium,(CAC)...

Other Medicine Technology:Diabetes drug supported by Mexican Diabetes Federation 2 Diabetes drug supported by Mexican Diabetes Federation 3 Arterial Plaque Significantly Reduced in Women Age 50-59 Taking,Hormones, Says New Analysis of Women's Health Initiative Data 2 Arterial Plaque Significantly Reduced in Women Age 50-59 Taking,Hormones, Says New Analysis of Women's Health Initiative Data 3

Diabetes drug supported by Mexican Diabetes Federation Arterial Plaque Significantly Reduced in Women Age 50-59 Taking,Hormones, Says New Analysis of Women's Health Initiative Data

(Date:12/2/2009)...linical trial presented today at the annual meetin...NA) provide the first strong evidence of the benef...ense breasts who are at elevated risk for breast c...s highly sensitive in depicting early breast cance...ound in addition to mammography significantly impr...

(Date:12/1/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, The Future of Central Nervous System ...Competitive Benchmarking, Product Pipeline and Dea...166814/The-Future-of-Central-Nervous-System-Diseas...tive-Benchmarking-Product-Pipeline-and-Deals-Analy...

(Date:12/1/2009)...wire-USNewswire/ -- The Kerlan Jobe Orthopaedic Cl... agreed to pay the United States $3 million to set... from HealthSouth Corporation, the Justice Departm...olves allegations that HealthSouth paid kickbacks ... donations to the Kerlan Jobe Foundation, loan for...

(Date:12/1/2009)...rths more likely, British study finds , ,...en who are poor are more likely to deliver a very ... both groups typically receive equal care, a new B...er research team said their findings show the need...mic status and preterm birth. , For the study, ...

(Date:12/1/2009)...ation Changes Name to HealthHIV , ...ation, one of the largest national HIV non-profit ...nd launching a new website. The announcement on Wo...n to promote the organization’s new vision a...uo;HealthHIV clearly, quickly and easily states ou...

[0] Annual screening with breast ultrasound or MRI could benefit some women [0] Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations [0] More Preemies Born Among the Poor [3] National HIV Non-Profit Announces New Name

... cancer is currently one of the most common male c...h in men.// Findings from a recent study suggests ... The study, conducted in a mouse model of human p...ke, growth-factor-driven pathway present in prosta...

...udy shows that low low-density lipoprotein, also k... by 10 percent // thereby improving the relative a...et that includes between eight and 10 walnuts a da...betes. A team of dieticians developed individua...

... ablation is a non-surgical technique used to elim...se abnormal heartbeats. // Researchers now say tha...atrial fibrillation a type of irregular heart rhyt...re who were undergoing catheter ablation for atria...

...ion to being at-risk for various health conditions... being accurately diagnosed // during medical imag...y obesity can limit the ability and accuracy of im... nearly doubled from 0.10 percent to 0.19 percent ...

... study shows chronic back pain shrinks the brain ...he degeneration of 10 to 20 years of aging.// ...tomated analysis techniques, researchers compared ...in for more than one year. The study showed tha...

...udy suggests young people are more likely to becom...form of a gene // that helps clear nicotine out of... CYP2A6 gene were about three-times more likely to...igarettes. In a study, carried out among seventh g...

Other Medicine News:

Green Tea Might Help Patients With Prostate Cancer Walnuts Could Aid Patients With Diabetes Catheter Ablation Helpful For Patients With Congestive Heart Failure Being Obese Increases Ones Risk Of A wrong Diagnosis During Medical Imaging Shrinkage Of Brain Size Linked To Chronic Pain Genes Linked To Cigarette Addiction

ZapICD

ZapBill Anesthesia

WardWatch v3.1.1

MedCalc 3000

Medicine Products:

ZapICD ZapBill Anesthesia WardWatch v3.1.1 MedCalc 3000

( pharmaceutical subsidiary of Eisai Co....)Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL),Health